Organization | United BioSource Corporation

United BioSource Corporation Report issue

For profit Phase 2 Phase 3

Founded: Blue Bell PA United States (2003)

Organization Overview

First Clinical Trial

2005

NCT00651833

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

United BioSource Corporation

Active Ingredients

Drugs in Phase 3 Trials (7)

dacarbazine (dtic-dome) (1 trial)

dulaglutide (trulicity) (1 trial)

ipilimumab (yervoy) (1 trial)

melphalan (alkeran) (1 trial)

pembrolizumab (keytruda) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 2 Trials (4)

gimeracil (3 trials)

oteracil (3 trials)

tegafur (3 trials)

Drugs in Other Trials (5)

armodafinil (nuvigil) (1 trial)

beclomethasone (vanceril) (1 trial)

modafinil (provigil) (1 trial)

natalizumab (tysabri) (1 trial)

onasemnogene abeparvovec (Zolgensma) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 3)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 16